Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 13/20 | 0.60 |
| ▸ | CRBN | Q96SW2 | 13/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22623691 | 0.80 | DDB1 (0.54) | DDB1CRBNHPGDBRD4CREBBP | |
| SCHEMBL22612103 | 0.80 | DDB1 (0.54) | DDB1CRBNHPGDBRD4CREBBP | |
| SCHEMBL22612113 | 0.78 | DDB1 (0.52) | DDB1CRBNBRD4CREBBP | |
| SCHEMBL24783462 | 0.76 | DDB1 (0.63) | DDB1CRBNBRD4CREBBP | |
| SCHEMBL19586142 | 0.75 | DDB1 (1.00) | DDB1CRBN | |
| SCHEMBL30273604 | 0.75 | DDB1 (1.00) | DDB1CRBN | |
| SCHEMBL20805180 | 0.75 | DDB1 (1.00) | DDB1CRBN | |
| SCHEMBL20805181 | 0.75 | DDB1 (1.00) | DDB1CRBN | |
| SCHEMBL24784156 | 0.75 | DDB1 (0.58) | DDB1CRBNBRD4CREBBP | |
| SCHEMBL24783432 | 0.74 | DDB1 (0.60) | DDB1CRBNBRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20220251061-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2022-08-11 | — | — | US | disclosed |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| EP-3710002-A2 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| CN-111372585-A | Degradants and degreddeterminants for target protein degradation | C4医药公司 | 2020-07-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234950-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885HPGD 4747/4885 |
| US-20200347045-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885HPGD 4747/4885 |
| US-12570626-B2 | Degraders and degrons for targeted protein degradation | ADRM1, UCHL3, USP30 | DDB1 1105/4885CRBN 25/4885HPGD 3116/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | DDB1 292/4885CRBN 37/4885HPGD 3751/4885 |
| US-20220251061-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | DDB1 292/4885CRBN 37/4885HPGD 3751/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | DDB1 292/4885CRBN 37/4885HPGD 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.